Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients
Table 2
Anthropometric, clinical, and biochemical parameters for placebo and resveratrol groups before and after resveratrol supplementation.
Control/placebo group
Intervention/resveratrol group
Baseline
After 45 days
P value
Baseline treatment
After treatment
P value
Body weight (kg)
0.809
0.712
BMI (kg/m2)
0.332
0.395
Systolic blood pressure (mmHg)
0.147
<0.0001*
Diastolic blood pressure (mmHg)
0.279
0.169
Fasting glucose (mg/dL)
0.002*
<0.0001*
Insulin (µIU/mL)
0.642
<0.0001*
HbA1c
0.764
<0.0001*
HOMA-IR
0.423
<0.0001*
HOMA-β
0.039
0.009*
Triglyceride (mg/dL)
0.145
0.051
Total cholesterol (mg/dL)
0.424
0.156
HDL-cholesterol (mg/dL)
0.133
0.001*
LDL-cholesterol (mg/dL)
0.003*
0.106
SGOT (IU/L)
0.212
0.837
SGPT (IU/L)
0.202
0.365
GGT (IU/L)
0.545
0.441
ALP (IU/L)
0.001*
0.372
Creatinine (mg/dL)
0.281
0.098
Data is presented as means ± SD. versus before treatment. HOMA-β: homeostasis model of assessment for beta cell function; HOMA-IR: homeostasis model of assessment for insulin resistance; HbA1c: Hemoglobin A1c; HDL: high density lipoprotein; LDL: low density lipoprotein; TG: triglyceride; SGOT: serum glutamate oxaloacetate transaminase; SGPT: serum glutamate pyruvate transaminase; GGT: gamma-glutamyltransferase; ALP: alkaline phosphatase.
